BIBLIOGRAFIA

BIBLIOGRAFIA

1. Beaglehole R, Bonita R, Horton R et al.; for The Lancet NCD Action Group and the NCD Alliance. Priority actions for the noncommunicable disease crisis. Lancet 2011; 377:1438–1447. 2. World Health Organization. Global burden of disease. 2012. Available from:http://www.who.int/topics/global _burden_of_ disease/en/ (accessed 6 March 2012) 3. World Health Organization. Global burden of disease. Preventing chronic diseases: a vital investment. 2005. Available from: http://www.who.int/chp/ chronic_disease_report/full_ report.pdf (accessed 6 March 2005 4. World Health Organization. Gaining Health: The European Strategy for the Prevention and Control of Noncommunicable Diseases. 2006. Available from: http://www.euro.who. int/__data/assets/pdf_file/0008/76526/E89306.pdf (accessed 6 March 2012). 5. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003; 348:383–393. 6. United Nations. General Assembly. Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Noncommunicable Diseases. 2011. Available from: http://www.un.org/en/ga/ ncdmeeting2011/ (accessed 6 March 2012). 7. World Health Organization. First Global Ministerial Conference on Healthy Lifestyles and Noncommunicable Disease Control. Discussion paper: Prevention and control of NCDs: priorities for investment. 2011. Available from: http://www.who.int/nmh/publications/who_bestbuys_to_preven t_ncds. pdf (accessed 6 March 2012). 8. United Nations. High-level Meeting on Non-communicable Diseases. 2011. Available from: http://www.un.org/en/ ga/president/65/issues/ncdiseases.shtml (accessed 6 March 2012). 9. Lindström J, Neumann A, Sheppard KE et al.; on behalf of the IMAGE Study Group. Take action to prevent diabetes - the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Hormone and Metabolic Research 2010; 42:S37–S57. 10. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 2001; 344:1343–1350. 11. Knowler W, Barrett-Connor E, Fowler S et al.; Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346[6]:393-403. 12. Lindström J, Ilanne-Parikka P, Peltonen M et al.; on behalf of the Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: the follow-up results of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673–1679. 13. Paulweber B, Valensi P, LindströmJ et al.; for the Writing Group on behalf of the IMAGE Study Group. A European evidence-based guideline for the prevention of type 2 diabetes. Hormone and Metabolic Research 2010; 42:S3–S37. 14. Organisation for Economic Co-operation and Development. OECD Health Ministerial Meeting. Session 2: Healthy Choices. 2010. Available from: http:// www.oecd.org/ dataoecd/14/13/46098333.pdf (accessed 6 March 2012). 15. Alberti KGMM, Zimmet P & Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabetic Medicine 2007; 24:451–463. 16. Internatinal Diabetes Federation. Global Diabetes Plan 20112021. 2011. Available from: http://www.idf.org/globaldiabetes-plan-2011-2021 (accessed 6 March 2012). 17. International Diabetes Federation. IDF Diabetes Atlas, 5th ed. Brussels, Belgium: International Diabetes Federation, 2011. 18. Busse R, Blümel M & Scheller-Kreinsen D. Tackling chronic disease in Europe: strategies, interventions and challenges. 2010. Available from: http://www. euro.who.int/__ data/assets/pdf_file/0008/96632/E93736.pdf (accessed 6 March 2012). 19. International Diabetes Federation. A Call to Action on Diabetes. 2010. Available from: http://www.idf.org/webdata/ Call-to-Action-on-Diabetes.pdf (accessed 6 March 2012). 20. Tal på diabetes 1996-2010, Sundhedsstyrelsen 2011. 21. Green, A.: Diabetes Mellitus i Danmark 1997-2006. Epidemiologiske Analyser 22. European Commission. Sustainable development in the European Union. 2011. Available from: http://epp.eurostat. ec.europa.eu/portal/page/portal/ product_details/publication? p_product_code=KS-31-11-224 (accessed 6 March 2012). 23. Davis TM. Ethnic diversity in type 2 diabetes. Diabet Med 2008; 25[(Suppl. 2)]: 52-56. 24. World Health Organization. Adherence to long-term therapies: Evidence for action. 2003 Available from: http://whqlibdoc.who.int/ publications/2003/9241545992.pdf (accessed 6 March 2012). 25. Varo JJ, Martinez-Gonález MA, Irala-Estévez J et al. Distribution and determinants of sedentary lifestyles in the European Union. International Journal of Epidemiology 2003; 32:138–146.

26. World Health Assembly. WHO global strategy on diet, physical activity and health. 2004. Available from: http://www.who.int/dietphysicalactivity/ strategy/eb11344/ strategy_english_web.pdf(accessed 6 March 2012). 27. Elmadfa I & Freisling H. Nutritional status in Europe: methods and results. Nutrition Reviews 2009; 67(Suppl. 1):S130–S134. 28. Schwarz PE, Greaves CJ, Lindström J et al. Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nature Reviews Endocrinology 2012; doi:10.1038/nrendo.2011.232.

29. Malnick S, Knobler H. The Medical Complications of Obesity. QJM 2006; 99[9]:565-579. 30. Abdullah A, Peeters A, de Courten M et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Research and Clinical Practice 2010; 89:309–319. 31. Organisation for Economic Co-operation and Development. Obesity and the Economics of Prevention. Available from: http://dx.doi. org/10.1787/9789264084865-en/content/book/ 9789264084865-en (accessed 6 March 2012). 32. International Obesity Task Force. EU Platform Briefing Paper. 2005. Available from: http://ec.europa.eu/health/ph_ determinants/life_style/nutrition/ documents/iotf_en.pdf (accessed 6 March 2012).

33. World Health Organization. Waist Circumference and WaistHip Ratio: Report of a WHO Expert Consultation. 2008. Available from: http://whqlibdoc.who. int/publications/2011/ 9789241501491_eng.pdf (accessed 6 March 2012). 34. Vazquez G, Duval S, Jacobs DR et al. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a metaanalysis. Epidemiologic Reviews 2007; 29:115–128. 35. Mackenbach JP. Health inequalities: Europe in profile. 2006. Available from: http://ec.europa.eu/health/ph_ determinants/socio_economics/documents/ ev_060302_rd06_ en.pdf (accessed 6 March 2012). 36. Wilkinson R, Marmot M (eds). Social Determinants of Health: the Solid Facts. 2nd ed. Available from: http://www.euro.who.int/__data/assets/pdf_ file/0005/98438/ e81384.pdf (accessed 6 March 2012). 37. Sheehy AM, Coursin DB, Gabbay RA et al. Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Mayo Clinic Proceedings 2009; 841:38–42. 38. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2005; 28(Suppl.):S4–S36.. 39. Holman R, Paul S, Bethel M et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589

40. Glumer C, Yuyun M, Griffin S et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006; 49:1536–1544. 41. Kahn R, Alperin P, Eddy D et al. Age at initiation and frequency of screening to detect type 2 diabetes: a costeffectiveness analysis. Lancet 2010; 375:1365–1374. 42. Bailey CJ & Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. International Journal of Clinical Practice 2011; 653:314–322. 43. Gherman A, Schnur J, Sassu R et al. How are adherent people more likely to think?: A meta-analysis of health beliefs and diabetes self-care. Diabetes Educator 2011; 373:392–408. 44. Peyrot M & Rubin RR. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study - response to Phillipov and Phillips. Diabetes Care 2006; 29:953. 45. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2005. Available from: http://www.idf.org/ webdata/docs/IDF%20GGT2D.pdf (accessed 6 March 2012). 46. World Health Organization. Innovative Care for Chronic Conditions: Building Blocks for Action. 2002. Available from: http://www.who.int/chp/knowledge/ publications/icccreport/en/ (accessed 6 March 2012). 47. International Alliance of Patients’ Organizations. Declaration on Patient-Centered Healthcare. 2006. Available from: http://www. patientsorganizations.org/attach.pl/547/ 269/ IAPO%20Declaration%20 on%20Patient-Centred%20 Healthcare%20-%20Colour.pdf (accessed 6 March 2012). 48. Asche C, LaFleur J & Conner C. Review of diabetes treatment adherence and the association with clinical and economic outcomes. Clinical Therapeutics 2011; 331:74–109. 49. Williams GC & Zeldman A. Patient-centered diabetes selfmanagement education. Current Diabetes Reports 2002; 22:145–152.

50. Norris SL, Chowdhury FM, Van Le K et al. Effectiveness of community health workers in the care of persons with diabetes. Diabetic Medicine 2006; 235:544–556. 51. Organisation for Economic Co-operation and Development. OECD Health Policy Studies - Improving Value in Health Care: Measuring Quality. 2010. Available from: http://www.oecd.org/health/measuringquality (accessed 6 March 2012). 52. Novo Nordisk A/S. Changing Diabetes® Barometer. 2012. Available from: http://www.changingdiabetesbarometer.com (accessed 6 March 2012). 53. Gudbjörnsdottir S, Cederholm J, Nilsson PM et al. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care 2003; 26:1270–1276. 54. Carstensen B, Christensen JK, Marcussen MM et al. The National Diabetes Register. Scandinavian Journal of Public Health 2011; 39 (Suppl.):58–61. 55. Det Nationale Indikatorprojekt. Det Nationale Indikatorprojekt: Hvad er det? Hvad får man? Hvad skal der ydes på afdelings-/sygehus- og regionalt niveau? 2007. Available from: http://www.nip.dk/files/Subsites/NIP/Om%20 NIP/ 20071214_NIP_Pixi.pdf (accessed 6 March 2012). 56. European Best Information through Regional Outcomes in Diabetes. Objectives. 2012. Available from: http://www.eubirod.eu/objectives.htm (accessed 6 March 2012). 57. Federation of European Nurses in Diabetes, International Diabetes Federation Europe. Diabetes. The Policy Puzzle: Is Europe Making Progress? 3rd ed. 2011. Available from: http://www.idf.org/sites/default/files/idf-europe/ThePolicy Puzzle Book.pdf (accessed 6 March 2012). 58. Huxley R. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73–78. 59. Ren J & Ceylan-Isik AF. Diabetic cardiomyopathy: do women differ from men? Endocrine 2004; 25:73–83. 60. Shea L & Owens-Gary M. Diabetes and depression in older women - double the risk, double the burden. Diabetes Voice 2009; 54:8–11. 61. Bellamy L, Casas J-P, Hingorani AD et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373:1773–1779. 62. Clausen TD, Mathiesen ER, Hansen T et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care 2008; 312:340–346. 63. Fetita LS, Sobngwi E, Serradas P et al. Consequences of fetal exposure to maternal diabetes in offspring. Journal of Clinical Endocrinology & Metabolism 2006; 91:618–624. 64. World Diabetes Foundation, Global Alliance for Women’s Health. Diabetes, women, and development. Meeting, expert recommendations for policy action, conclusions, and follow-up actions. International Journal of Gynecology & Obstetrics 2009; 104:S46–S50.

65. Hanson MA & Gluckman PD. Developmental origins of noncommunicable disease: population and public health implications. American Journal of Clinical Nutrition 2011; 94(6

Suppl.):1754S–1758S. 66. Keeling A & Dain K. IDF: putting women and diabetes on the global agenda. Diabetes Research and Clinical Practice 2010; 89:196–199.

67. Haines L, Wan KC, Lynn R et al. Rising incidence of type 2 diabetes in children in the U.K. Diabetes Care 2007; 30:1097–1101

68. Sinnott M, Carr BM, Walsh C et al. Combination of FINDRISC and fasting plasma glucose (FPG) in screening for type 2 diabetes in an Irish population: the type 2 diabetes mellitus and vascular health initiative (DMVHI). Diabetologia 2011; 54(Suppl. 1):S102. 69. The AMD Annals 2010 Working Group & Cimino A, Fava D, Giorda CB et al. AMD Annals 2010: Quality Indicators in Diabetes Care in Italy. 2010. Available from: http://infodiabetes.it/files/Annali_2010_inglese_II.pdf (accessed 6 March 2012). 70. Goldfracht M, Levin D, Peled O et al. Twelve-year follow-up of a populationbased primary care diabetes program in Israel. International Journal for Quality in Health Care 2011; 236:674–681.

71. Gillett M, Dallosso HM, Dixon S et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ 2010; 341:c4093 72. World Health Organization. Diabetes Care and Research in Europe: The St Vincent Declaration 1989. Available from: http://www.idf.org/webdata/docs/ SVD%20and%20Istanbul %20Commitment.pdf (accessed 6 March 2012). 73. European Parliament. Declaration of the European Parliament on diabetes. 2006. Available from: http://www.europarl.europa.eu/sides/getDoc. do?reference=P6_ TA (2006)0185&language=EN (accessed 6 March 2012). 74. Council of the European Union. Council Conclusions on promotion of healthy lifestyles and prevention of type 2 diabetes. 2006. Available from: http:// www.consilium.europa.eu/ uedocs/cms_ Data/ docs/pressdata/en/lsa/89847.pdf (accessed 6 March 2012). 75. United Nations. United Nations Resolution 61/225: World Diabetes Day. 2007. Available from http://www. worlddiabetesfoundation.org/media(3892,1033)/ UNR_media_ kit_0407.pdf (accessed 6 March 2012). 76. Council of the European Union. Council conclusions “Innovative approaches for chronic diseases in public health and healthcare systems”. 2010. Available from: http://whatsnew. eucomed.org/wp-content/uploads/ 2010/12/101215_ council_ conclusions_chronic_diseases__071210.pdf (accessed 6 March 2012). 77. European Parliament. EU position and commitment in advance of the UN high-level meeting on the prevention and control of non-communicable diseases. 2011. Available from: http://www.europarl.europa.eu/sides/ getDoc.do?pubRef=//EP//TEXT+TA +P7-TA -2011-0390+0+DOC+XML+V0// EN&language=EN (accessed 6 March 2012). 78. The Emerging Risk Factors Collaboration. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. N Engl J Med 2011; 364:829-841. 79. Stratton IM, Adler AI, Neil AW et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–412. 80. Gæde P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008; 358:580–591. 81. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703–713.

82. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008; 358:2545–2559. 83. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008; 358:2560–2572. 84. Duckworth W, Abraira C, Moritz T et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009; 360:129–139.

85. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765–1772. 86. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288-98. 87. Holman N, Forouhi NG, Goyder E et al. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030. Diabetic Medicine 2011; 28;575–582. 88. Pyorala K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614–620.

89. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253–259. 90. Egede LE, Zheng D & Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002; 25:464–470. 91. de Groot M, Anderson R, Freedland KE et al. Association of depression and diabetes complications: a meta-analysis. Psychosomatic Medicine 2001; 63:619–630. 92. Lin EH, Katon W, Von Korff M et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004; 27:2154–2160. 93. Gannon B & Nolan B. Disability and labor force participation in Ireland. The Economic and Social Review 2004; 35:135–155. 94. Koopmanschap M. Coping with type II diabetes: the patient’s perspective. Diabetologia 2002; 45:S18–S22. 95. Kanavos P, van den Aardweg S & Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. 2012. Available from: http://www2.lse.ac. uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/ LSEDiabetesReport26Jan2012.pdf (accessed 6 March 2012).

96. Lauro.R., Nicolucci. A et all “Facts and Figures about the diabetes in Italy 2011 Public Health and Health Policy (June 212) 97. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. 98. ISTAT. Annuario statistico italiano 2010. http://www.istat.it/dati/catalogo/20101119_00/PDF/cap3.pdf 99. Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Cortesi L, Riva E, Fortino I, Bortolotti A, Fontana G, Merlino L, Roncaglioni MC. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med. 2012;29:385-92 100. Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G. Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study. Nutr Metab Cardiovasc Dis. 2008;18:678-82. 101IDF Diabetes Atlas. www.eatlas.idf.org/ 102. http://demo.istat.it/ 103. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M; Bruneck study. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53:1782-9. 104. http://www.istat.it/dati/catalogo/20100319_01/ 105. http://www.epicentro.iss.it/okkioallasalute/default.asp 106. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. 107. Rapporto Sociale Diabete 2003. www.diabete.it/files/RapportoSocialeDiabete2003.pdf 108. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MCE, Sacco M, Tognoni G, Valentini M, Nicolucci A. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care 2005; 28:1643-1649. 109. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, Trevisan R, Vedovato M, Cignarelli M, Andreozzi F, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Diabetes Care 2012;35:143-9. 110. De Berardis G, D’Ettorre A, Graziano G, Lucisano G, Pellegrini F, Cammarota S, Citarella A, Germinario CA, Lepore V, Menditto E, Nicolosi A, Vitullo F, Nicolucci A; for the DADA (Diabetes Administrative Data Analysis) Study Group. The burden of hospitalization related to diabetes mellitus: A population-based study. Nutr Metab Cardiovasc Dis. 2011 Feb 16. [Epub ahead of print] 111. Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M; on behalf of the ARNO Working Group. The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutr Metab Cardiovasc Dis. 2011;21: 339-46. 112. Profili di assistenza e costi del diabete in Emilia Romagna. http://asr.regione.emiliaromagna.it/wcm/asr/collana_dossier/doss179/link/doss179.pdf 113.Bruno G, Picariello R, Petrelli A, Panero F, Costa G, CavalloPerin P, Demaria M, Gnavi R. Direct costs in diabetic and non diabetic people: The population-based Turin study, Italy. Nutr Metab Cardiovasc Dis. 2011 Sep 8. [Epub ahead of print] 114. VI report Health Search. I costi per patologia: il caso dei pazienti diabetici. http://www.healthsearch.it/documenti/ Archivio/Report/VIReport_2009-2010/HS_VReport2010_ HiRe s.pdf 115. Osservatorio ARNO Diabete. Il profilo assistenziale della popolazione con diabete. Rapporto 2011 Volume XVII - Collana “Rapporti ARNO”. 116. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. CODE-2 Italian Advisory Board. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treatments in Endocrinology 2003;2:121e33. 117. http://www.euro.who.int/__data/assets/pdf_file/0003/ 98391/E93348.pdf 118. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008;25:245-54. 119. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W et al. for the DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. Diabetes Care 2003; 26: 1176–1180.

120. Leiter LA, Yale J-F, Chiasson J-L, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005; 29:186–192. 121. P.G. Kanavos, S. van den Aardweg, W.G. Schurer. Burden of disease, cost and management of diabetes in EU5 countries. Presented at the 47th EASD Meeting, 12-16 September 2011, Lisbon.

122. Waugh N et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007; 11(17):iii-iv, ix-xi, 1-125. 123. Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Aff (Millwood) 2008;27(1):256-68. 124. Gillies CL et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 336(7654):1180-5. 125. Piano Sanitario Nazionale 2011-2013. http://www.sanita.ilsole24ore.com/Sanita/Archivio/Normativa% 20e%20varie/PSN%202011%202013.pdf?cmd=art&codid=24. 0.2358998884

126. Di Pietro S, Comaschi M, Coscelli C, Cucinotta D, Giorda C, Noacco C, Vespasiani G, Nicolucci A; DIANEO Study Group. Clinical characteristics and patterns of care of newly diagnosed type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17:e31-3. 127. Diabetes monitor

128. Franciosi M, De Berardis G, Rossi MCE, Sacco M, Belfiglio M, Pellegrini F, Tognoni G, Valentini M, Nicolucci A. The use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance. The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational Study) Study. Diabetes Care 2005;28:1187-94. 129. Annali AMD 2010. http://infodiabetes.it/files/ANNAL I2010.pdf 130. VI Report Health Search. http://www.healthsearch.it/

documenti/Archivio/Report/VIReport_2009-2010/HS_VReport2010_HiRes.pdf 131. Club Diabete Sicili@. Five-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics. Diabetes Care. 2008;31:57-62. 132. Giorda C, Picariello R, Nada E, Tartaglino B, Marafetti L, Costa G, Gnavi R. The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS ONE 7(4): e33839. 133. Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Vitali L, Bulotta A, Nicoziani P, Coronel G; on behalf of the QuoLITy Study Group. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19:4553.

134. EQuality1 Study Group—Evaluation of QUALITY of Life and Costs in Diabetes Type 1, Nicolucci A, Maione A, Franciosi M, Amoretti R, Busetto E, Capani F, Bruttomesso D, Di Bartolo P, Girelli A, Leonetti F, Morviducci L, Ponzi P, Vitacolonna E. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med. 2008;25:21320.

135. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A; QuED (Quality of Care and Outcomes in Type 2 Diabetes) Study Group. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care. 2005;28:263743.

136. Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Cavaliere D, Di Nardo B, Greenfield S, Kaplan SH, Sacco M, Tognoni G, Valentini M, Nicolucci A; QuED Study Group. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: an urgent need for better educational strategies. Diabetes Care. 2001;24:1870-7 137. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23:1165-73. 138. Studio DAWN Italia. http://www.dawnstudyitaly. com/DAWN-Italy.pdf 139. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21:1477-83. 140. Haugstvedt A, Wentzel-Larsen T, Graue M, Søvik O, Rokne B. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010;27:72-8 141. Di Battista AM, Hart TA, Greco L, Gloizer J. Type 1 diabetes among adolescents: reduced diabetes self-care caused by social fear and fear of hypoglycemia. Diabetes Educ. 2009;35:465-75 142. Standard Italiani per la cura del Diabete Mellito. http://www.changingdiabetesbarometeritaly.com/pdf/nuovi/doc umenti/Standard-di-cura-2009.pdf 143. Rossi MC, Nicolucci A, Arcangeli A, Cimino A, De Bigontina G, Giorda C, Meloncelli I, Pellegrini F, Valentini U, Vespasiani G; Associazione Medici Diabetologi Annals Study Group. Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics. Diabetes Care. 2008;31:2166-8. 144. Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 2008;31:1046-50. 145. Rubin RR, Peyrot M, Siminerio LM. Health care and patientreported outcomes: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care 2006;29:1249-55. 146. Osservatorio civico sul federalismo in sanità. Rapporto 2011. http://www.sanita.ilsole24ore.com/Sanita/Archivio/Normativa% 20e%20varie/osservatorio%20cittadinazattiva%202011.pdf?c md=art&codid=26.0.3639004132

147. http://www.aemmedi.it/linee-guida-e-raccomandazioni/ pdf/2010-documento_indirizzo.pdf 148. Musacchio N, Lovagnini Scher A, Giancaterini A, Pessina L, Salis G, Schivalocchi F, Nicolucci A, Pellegrini F, Rossi MC. Impact of a chronic care model based on patient empowerment on the management of Type 2 diabetes: effects of the SINERGIA programme. Diabet Med 2011 Feb 5. 149. http://www.senato.it/documenti/repository/commission i/comm12/documenti_acquisiti/Documento%20per%20audizio ne.pdf 150. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N 151. Istituto Nazionale di Statistica – Istituto Superiore di Sanità. Impatto dell’epidemia Covid-19 sulla mortalità: cause di morte nei deceduti positivi a SARS-Cov-2 https://www.istat.it/it/files//2020/07/Report_ISS_Istat_Cause-dimorte-Covid.pdf 152. Annali AMD 2018. Valutazione degli indicatori AMD di qualità dell’assistenza al diabete in Italia. https://aemmedi.it/wpcontent/uploads/2018/11/Annali_AMD-_2018_prot.pdf 153. Penno G, Solini A, Bonora E, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013;274:176-191. 154. 1st Italian Obesity Barometer Report. Obesity Monitor Vol.1; 2019. https://www.diabete.com/wp-content/uploads/ 2019/04/OBESITY-BAROMETER-REPORT-4-4-2019-LOW.pdf 155. European Commission. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Short-term EU health preparedness for COVID19 outbreaks. https://ec.europa.eu/info/sites/info/files/ communication_-_short-term_eu_health_preparedness.pdf 156. Annali AMD 2018. Valutazione degli indicatori AMD di qualità dell’assistenza al diabete in Italia. https://aemmedi.it/wpcontent/uploads/2018/11/Annali_AMD-_2018_prot.pdf 157. Le Monografie degli Annali AMD 2012. Cambiamento delle terapie nel diabete di tipo 2. https://aemmedi.it/wp-

content/uploads/2016/09/Annali-2013-Terapie-per-web.pdf 158. Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015; 14: 100.

159. Fritzen K, Heinemann L, Schnell O. Modeling of diabetes and its clinical impact. J Diabetes Sci Technol 2018;12:976–984. 160. Baxter M, Hudson R, Mahon J, et al. Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med 2016;33:1575–1581.

161. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: Impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416–426. 162. Chou R, Baker WL, Banez LL, et al. Agency for healthcare research and quality evidence based practice center methods provide guidance on prioritization and selection of harms in systematic reviews. J Clin Epidemiol 2018; 98:98–104. 163. Zafar A, Davies M, Azhar A, et al. Clinical inertia in management of T2DM. Prim Care Diabetes 2010; 4:203–207. 164. Brod M, Pfeiffer KM, Barnett AH, et al. Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom.Curr Med Res Opin. 2016;32:981-9. 165. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–9. 166. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab 2019;10:1–11. 167. Polonsky WH and Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 2016; 22:1299–1307. 168. Laursen DH, Christensen KB, Christensen U, Frølich A. Assessment of short and long-term outcomes of diabetes patient education using the health education impact questionnaire (HeiQ). BMC Res Notes 2017;10:213. 169. Russell-Jones D, Pouwer F and Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 2018;20:488–496. 170. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and SodiumGlucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139:2022-2031. 171. Nicolucci A, Rossi MC. Il diabete: una sfida per i sistemi sanitari. Italian Health Policy Brief 2014. http://www.ibdo.it/pdf/policy-brief/002Speciale_IHPB_2014_DEF_03_Print.pdf 172. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. AMA Intern Med 2015;175:356–362. 173. Khunti K and Davies MJ. Clinical inertia: time to reappraise the terminology? Prim Care Diabetes 2017; 11: 105–106.

Con il contributo non condizionato di